Abstract
ObjectivesTo evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA).MethodsThis double-blind study...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have